Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction

Journal of Endocrinological Investigation

Volumn 35, Issue 10, 2012, Pages 915-920

  Corona, G ^a,b   Rastrelli, G ^a   Maseroli, E ^a   Balercia, G ^c   Sforza, A ^b   Forti, G ^d   Mannucci, E ^d   Maggi, M ^a  

^a Department of Clinical Physiopathology ^*  (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

5ARI; Sexual dysfunction

Indexed keywords

DUTASTERIDE; FINASTERIDE; SEX HORMONE BINDING GLOBULIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; EJACULATION; ERECTILE DYSFUNCTION; GYNECOMASTIA; HELP SEEKING BEHAVIOR; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MEDICAL CARE; PERCEIVED REDUCED SLEEP RELATED ERECTION; PREMATURE EJACULATION; RETROSPECTIVE STUDY; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SIDE EFFECT; SMOKING; TREATMENT OUTCOME;

5-ALPHA REDUCTASE INHIBITORS; AGED; AZASTEROIDS; CASE-CONTROL STUDIES; CHOLESTENONE 5 ALPHA-REDUCTASE; EJACULATION; ERECTILE DYSFUNCTION; FINASTERIDE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; RISK FACTORS; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SLEEP DISORDERS; TESTOSTERONE;

EID: 84871910438     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8510     Document Type: Article

References (41)

1. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010, 33: 475-88.
2. Emberton M, Fitzpatrick JM, Rees J. Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int 2011, 107: 876-80.
3. Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010, 28: 9-15.
4. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of PC. N Engl J Med 2003, 349: 215-24.
5. Anitha B, Inamadar AC, Ragunatha S. Finasteride-its impact on sexual function and prostate cancer. J Cutan Aesthet Surg 2009, 2: 12-6.
6. Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol 2002, 2: 14.
7. Erdemir F, Harbin A, Hellstorm WJ. 5a reductase inhibitors and erectile dysfunction: The connection. J Sex Med 2008, 5: 2917-24.
8. Canguven O, Burnett AL. The effect of 5 alpha-reductase inhibitors on erectile function. J Androl 2008, 29: 514-23.
9. Gormley GJ, Stoner E, Bruskewitz RC, et al Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia: The Finasteride study group. N Engl J Med 1992, 327: 1185-91
10. Nickel JC, Fradet Y, Boake RC, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996, 155: 1251-9. (Pubitemid 26392086)
11. Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998, 34: 169-75. (Pubitemid 28432911)
12. Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the prostate cancer prevention trial. J Natl Cancer Inst 2007, 99: 1025-35. (Pubitemid 47232603)
13. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994, 43: 284-92.
14. Wessels H, Roy J, Bannow J, et al PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo treated men with benign prostatic hyperplasia. Urology 2003, 61: 579-84. (Pubitemid 36294195)
15. Tosti A, Pazzaglia M, Soli M, et al. Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol 2004, 140: 857-8. (Pubitemid 38917855)
16. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 2010, 146: 1141-50.
17. Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon? J Sex Med 2007, 4: 1708-12. (Pubitemid 47616863)
18. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004, 63: 709-15. (Pubitemid 38479415)
19. Andriole GL, Kirby R. Safety and tolerability of the dual 5 alphareductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003, 44: 82-8. (Pubitemid 36741378)
20. Goldstein I. An old problem with a new cause-5 alpha reductase inhibitors and persistent sexual dysfunction. J Sex Med 2011, 8: 1829-31.
21. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011, 8: 872-84.
22. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med 2011, 8: 1747-53.
23. Uygur MC, Arik AI, Altug U, Erol D. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids 1998, 63: 208-13. (Pubitemid 28198941)
24. Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007, 92: 1659-65. (Pubitemid 46997168)
25. Petrone L, Mannucci E, Corona G, et al. Structured interview on erectile dysfunction (SIEDY): a new, multi-dimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res 2003, 15: 210-20. (Pubitemid 36928914)
26. Corona G, Jannini EA, Maggi M. Inventories for male and female sexual dysfunctions. Int J Impot Res 2006, 18: 236-50.
27. Corona G, Ricca V, Bandini E, et al. Association between psychiatric symptoms and erectile dysfunction. J Sex Med 2007, 5: 458-68.
28. Corona G, Petrone L, Mannucci E, et al. Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol 2004, 46: 615-22. (Pubitemid 39345733)
29. Corona G, Ricca V, Boddi V, et al. Autoeroticism, mental health, and organic disturbancies in patients with erectile dysfunction. J Sex Med 2010, 7: 182-91.
30. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84: 3666-72. (Pubitemid 30645223)
31. Corona G, Fagioli G, Mannucci E, et al. Penile doppler ultrasound in patients with erectile dysfunction (ED): role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J Sex Med 2008, 5: 2623-34.
32. Seftel AD. Diagnosis of Erectile Dysfunction. In: Porst H, Buvat J, ed. Standard Practice in Sexual Medicine. Malden (USA): Blackwell Publishing. 2006, p 67.
33. Hatzichristou D, Rosen R, Derogatis L, et al. Clinical evaluation and symptom scales in men and women with sexual dysfunction. In: Adaikan G, Basson R, Becher E, et al. (eds). Sexual Medicine: sexual dysfunctions in men and women. The 3rd International Consul - tation on Sexual Medicine. Paris, France: Health Publication Ltd. 2010, pp. 229-80.
34. Andriole GL, Bostwick DG, Brawley OW, et al REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362: 1192-202.
35. Pinsky MR, Gur S, Tracey AJ, Harbin A, Hellstrom WJ. The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med 2011, 8: 3066-74.
36. Corona G, Rastrelli G, Balercia G, et al. Perceived reduced sleeprelated erections in subjects with erectile dysfunction: psychobiological correlates. J Sex Med 2011, 8: 1780-8.
37. Jannini EA, Granata AM, Hatzimouratidis K, Goldstein I. Use and abuse of Rigiscan in the diagnosis of erectile dysfunction. J Sex Med 2009, 6: 1820-9.
38. Cunningham GR, Hirshkowitz M. Inhibition of steroid 5 alpha-reductase with finasteride: sleep-related erections, potency, and libido in healthy men. J Clin Endocrinol Metab 1995, 80: 1934-40.
39. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. How to recognize late onset hypogonadism in men with sexual dysfunction. Asian J Androl 2012, 14: 251-9.
40. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010, 7: 46-56.
41. Azzouni F, Godoy A, Li Y, Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol 2012, 2012: 530121.